NASDAQ · Biotechnology

Allakos Inc. (ALLK) Stock

$0.33 +0.22% NASDAQ: ALLK Healthcare

Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents.

Valuation

MetricValue
Price$0.33
Market Cap$29.74M
P/E Ratio-0.25
P/B Ratio0.37
P/S Ratio0.00
EPS (TTM)$-1.30
52-Week High$1.56
52-Week Low$0.22
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-93.54%
ROA-119.89%
ROCE-155.07%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio4.81

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-157.0M$-271.0M$-322.0M$-196.0M$-122.0M
Net Profit$-153.0M$-270.0M$-320.0M$-186.0M$-116.0M
EPS$-3.10$-5.01$-5.06$-2.14$-1.30
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$720.0M$535.0M$386.0M$244.0M$97.0M
Total Liabilities$65.0M$89.0M$76.0M$75.0M$18.0M
Cash$207.0M$153.0M$87.0M$66.0M$18.0M
Borrowings$43.0M$51.0M$49.0M$41.0M$4.0M

Latest News

OP Pohjola's President and Group CEO Timo Ritakallio has announced that he will retire on 1 July 2027 as specified in his executive contract GlobeNewswire · Jul 23, 2026 Tocvan Discovers New High-Grade At-Surface Silver-Gold Zone 900 m East of Pilot Facility at Gran Pilar Project ACCESS Newswire · Jul 23, 2026 Constellation Brands Shareholders Approve Directors, Pay and Incentive Plan at Annual Meeting MarketBeat · Jul 23, 2026 Eco (Atlantic) Oil and Gas Ltd Announces Audited Results for the Year Ended 31 March 2026 ACCESS Newswire · Jul 23, 2026 OP Corporate Bank plc's Half-year Financial Report 1 January–30 June 2026 GlobeNewswire · Jul 23, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-114.0M$-208.0M$-280.0M$-116.0M$-94.0M
Investing Cash Flow$3.0M$110.0M$63.0M$93.0M$45.0M
Financing Cash Flow$7.0M$10.0M$-139.0M$2.0M$0
Net Cash Flow$169.0M$-54.0M$-66.0M$-21.0M$-49.0M
Free Cash Flow$-115.0M$-241.0M$-288.0M$-117.0M$-94.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.15
FCF Yield-315.18%
Quick Ratio4.81
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGTCApplied Genetic Technologies Corporation $0.39 +0.00% -0.25 $0 0.00%
ANGNAngion Biomedica Corp. $1.00 +0.00% -0.42 $30.11M 0.00%
ELEVElevation Oncology, Inc. $0.37 -2.12% -0.47 $21.63M 0.00%
FRLNFreeline Therapeutics Holdings plc $6.49 +0.15% -0.29 $28.28M 0.00%
HARPHarpoon Therapeutics, Inc. $23.01 +0.09% -1.14 $865.08M 0.00%

About Allakos Inc.

Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a Phase II trial for atopic dermatitis and chronic spontaneous urticaria. Furthermore, Allakos is exploring lirentelimab (AK002) for potential use in mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In parallel, their pipeline includes AK006, another candidate being developed to tackle various allergic and inflammatory diseases. Established in 2012, Allakos Inc. operates from its headquarters located in Redwood City, California.

Allakos Inc. is headquartered in US.

Allakos Inc. (ALLK) stock trades at $0.33 with a market capitalization of $29.74M. The stock is valued at a price-to-earnings (P/E) ratio of -0.25, price-to-book of 0.37, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.22 and $1.56, and currently trades 78.8% below its 52-week high.

On profitability, Allakos Inc. generates a return on equity (ROE) of -93.54%, return on capital employed of -155.07%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.allakos.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides